Investigating how two receptors affect the development of Type One Diabetes
Official title: Targeting the Opposing Roles of Prostaglandin E2 Receptors, EP3 and EP4, in the Pathogenesis of Type One Diabetes
Funded at Vanderbilt University · NIH-11055274 · Data updated 2026-11-12
This study is looking at how two specific receptors in the body can help protect the insulin-producing cells in people with Type One Diabetes, with the hope of finding better ways to treat or even reverse the condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | March 1, 2024 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $34,814 |
| NIH project number | 5F31DK138714-02 |
| Project ID | NIH-11055274 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Type One Diabetes who are seeking new treatment options.
✕Less likely to help
Patients with Type Two Diabetes or those without an autoimmune component to their diabetes may not benefit from this research.
What this research studies
This research focuses on Type One Diabetes (T1D), an autoimmune disease that leads to the destruction of insulin-producing cells in the pancreas. The study aims to explore the roles of two receptors, EP3 and EP4, which respond to a signaling molecule called Prostaglandin E2 (PGE2). By blocking the EP3 receptor and enhancing the EP4 receptor, the research seeks to promote the health and survival of pancreatic beta cells, potentially preventing or reversing the disease. The approach combines targeting the immune response with improving beta cell function, which may offer a more effective treatment strategy for T1D.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reverse Type One Diabetes, improving the quality of life for patients.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways for diabetes treatment, indicating potential for success in this approach.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Burkett, Juliann B — Vanderbilt University
- Study coordinator: Burkett, Juliann B
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.